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2275Atrial ﬁbrillation (AF) increases the risk of stroke and death
and consequently constitutes a signiﬁcant societal health and
economic problem (1,2). Prediction of a patient’s risk of
stroke is most commonly made using a clinical score such as
the CHADS2 or CHA2DS2VASc (heart failure, hyperten-
sion, age 75 years and older, diabetes, and previous stroke or
transient ischemic attack, vascular disease, age 65 to 74
years, sex category [female sex], respectively) (3,4). B-type
natriuretic peptides are secreted by myocytes in response to
a number of stimuli including an increase in wall stress (5).
Their secretion increases with aging and with left ventricular
hypertrophy and in acute coronary syndromes, heart failure,
chronic kidney disease, and AF (6,7). In these conditions,
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is
a powerful predictor of prognosis (8–15). However, little is
known about the predictive value of NT-proBNP in patients
with AF in whom, at present, risk stratiﬁcation based on
clinical scores only offers a modest discriminating ability for
the individual patients (4).
See page 2285
In the ARISTOTLE (Apixaban for the Prevention of
Stroke in Subjects With Atrial Fibrillation) trial (16), we
obtained plasma samples for central biomarker analyses from
14,892 of 18,201 patients. In this pre-speciﬁed substudy, we
examinedwhetherNT-proBNPmight predict the occurrence
of stroke and other nonfatal and fatal cardiovascular events in
anticoagulated patients with AF and an increased risk of
stroke. We further tested the incremental value of measuring
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score) to predict cardiovascular
and bleeding events.Methods
The ARISTOTLE trial. The
details of the ARISTOTLE trial
were published previously (16).
Brieﬂy, the ARISTOTLE trial
was a double-blind, double-dum-
my, randomized clinical trial that
enrolled 18,201 patients with AF
and at least 1 CHADS2 risk factor
for stroke or systemic embolism.
Patients were randomized to war-
farin (n ¼ 9,081) or apixaban (n ¼ 9,120). The primary
endpoint was stroke or systemic embolism. Bleeding was
classiﬁed according to the International Society onThrombosis
and Haemostasis (ISTH) criteria. The median length of
follow-up was 1.9 years in the biomarker study.
Endpoints and clinical risk classiﬁcation. The endpoints
in the ARISTOTLE trial included stroke or systemic
embolism; ischemic stroke and systemic embolism, hemor-
rhagic stroke, myocardial infarction; all-cause mortality;
cardiac death (excluding bleeding and other noncardiac
causes); ISTH major bleeding; and composites including
stroke or systemic embolism, total death or cardiac death, and
myocardial infarction. All endpoints were adjudicated by
a blinded clinical events committee using pre-speciﬁed
criteria (16). CHADS2 and CHA2DS2VASc scores were
calculated for each patient based on the sum of the corre-
sponding risk factors present at randomization. Patients were
categorized by CHADS2 according to score (0 to 1, 2, or3)
and by CHA2DS2VASc scores (0 to 1, 2, 3, 4, and 5).
Biochemical methods. For the ARISTOTLE biomarker
substudy, baseline blood samples were obtained from 14,892
patients. Plasma was frozen in aliquots and stored at 70C
until analyzed centrally. The NT-proBNP levels were deter-
mined with sandwich immunoassays on the Cobas Analytics
e601 Immunoanalyzers (Roche Diagnostics, Mannheim,
Germany) according to manufacturer instructions. The lower
limit of detection for NT-proBNP with this assay is 5 ng/l.
The analytical range extends from 20 to 35,000 ng/l according
to the manufacturer. The upper reference level (97.5th
percentile) in men and women 40 to 65 years of age is 184
and 268 ng/l, respectively, and 66 to 76 years of age, 269 and
391 ng/l, respectively (17). The lowest concentration with
a coefﬁcient of variation <10% is 30 ng/l (18).
Statistical analyses. These analyses included the 14,892
patients who provided blood samples for the biomarker
study at randomization and also had available results of the
evaluated biomarkers. Demographics and other baseline
characteristics were summarized using frequencies for cate-
gorical variables and median and 25th and 75th percentiles
for continuous variables. For tests of differences among
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2276groups, the chi-square test was used for categorical variables
and the Kruskal-Wallis test was used for continuous
variables.
Multivariable analysis of variance with natural logarithms
of NT-proBNP as response variables and categorized base-
line characteristics as explanatory variables was used to
investigate the independent effect of each variable. Geo-
metric means, calculated by antilogs of the model-adjusted
means, were compared.
Efﬁcacy analyses included all randomized patients and
included all events from randomization until the efﬁcacy
cut-off date (pre-deﬁned as January 30, 2011). Bleeding
analyses were ‘on treatment’ including all randomized
patients who received at least 1 dose of study drug and
included all events from receipt of the study drug until 2
days after the last dose of the study drug.
The relationship between NT-proBNP and outcomes
was evaluated both in a simple and multivariable Cox
regression analysis. The multivariable analyses included
established risk factors (age, sex, body mass index, smoking
status, systolic blood pressure, heart rate, AF type, diabetes,
heart failure, previous stroke/systemic embolism/transient
ischemic attack, hypertension, previous myocardial infarc-
tion, previous peripheral arterial disease, coronary artery
bypass grafting/percutaneous coronary intervention, treat-
ment at randomization with aspirin, angiotensin-converting
enzyme inhibitor or angiotensin II receptor blocker, and
amiodarone), randomized treatment, region, use of warfarin
within 7 days before randomization, use of statin medica-
tion within 30 days before randomization score, and
biomarkers (cystatin C and high-sensitivity troponin T).
For the major bleeding endpoint, a history of anemia and of
spontaneous or clinical relevant bleeding was also included
in the established risk factors and the multivariable analysis.
The hazard ratios (HRs) and 95% conﬁdence intervals
(CIs), using the group with the lowest biomarker levels as
reference, were reported. The assumption of proportional
hazards for the factors included in the Cox regression
analyses was assessed visually using log-cumulative hazard
plots (not shown).
Treatment effects were compared according to the
NT-proBNP group using a Cox proportional hazards model
including treatment group, NT-proBNP quartile group, and
treatment by NT-proBNP interaction as covariates. The
treatment HRs are reported at each level of NT-proBNP,
regardless of the signiﬁcance of interaction.
The incidences of the different endpoints were summa-
rized in relation to randomized treatment, quartiles of the
NT-proBNP level, and CHA2DS2VASc scores.
The increased discriminative values of adding NT-
proBNP level to models with only a CHA2DS2VASc
score and study treatment were investigated by estimating
the difference in C-statistics between models with and
without NT-proBNP levels and also the integrated dis-
crimination improvement measure (IDI), as described by
Pencina et al. (19,20). In these analyses, the occurrence/nonoccurrence of an event during the follow-up period was
used as a binary response, and the C value will be the same as
the area under the receiver-operating characteristic curve. The
relative IDI was calculated to facilitate interpretation of the
IDI (21). In addition, continuous (category-free) net reclas-
siﬁcation improvement (NRI) was analyzed as a measure of
probability of better reclassiﬁcation minus the probability of
worse reclassiﬁcation with the new model. The NRI among
events and nonevents as well as the total NRI were analyzed.
Kaplan-Meier estimates of the cumulative risk to the ﬁrst
occurrence of an event were calculated and plotted. Event
rates per 100 patient-years of follow-up were reported. All
statistical tests were 2 tailed and performed at the 0.05
signiﬁcance level. There were no adjustments for multiple
comparisons. The Clinical Trials section at Uppsala
Clinical Research Center conducted the statistical analyses,
using the statistical software package SAS, version 9.3 for
Windows (SAS Institute, Cary, North Carolina) for all
analyses.Results
Baseline characteristics and distribution levels of
NT-proBNP. The median NT-proBNP concentration
was 714 ng/l (25th and 75th percentiles ¼ 363 and
1,250 ng/l), and there was no difference between the
warfarin and apixaban groups. The 25th percentile value was
close to the upper reference level of NT-proBNP in healthy
subjects (i.e., 75% of patients had an elevated level) (17).
Baseline characteristics according to NT-proBNP quar-
tiles are shown in Table 1. Many characteristics were asso-
ciated with NT-proBNP in univariate analysis, with higher
levels in older subjects and women and in patients with
other cardiovascular disease, diabetes, and renal dysfunction.
NT-proBNP was also related to AF type. These baseline
characteristics remained associated with the NT-proBNP
level in a multivariable analysis (p < 0.05 for all). The
strongest relationship was with AF type, with a more than
3-fold higher geometric mean NT-proBNP in patients
with persistent/permanent AF compared with paroxysmal
AF (ratio of geometric means: 3.35; 95% CI: 3.22 to 3.50;
p < 0.0001), followed by reduced creatinine clearance
(Cockcroft-Gault), heart failure, and age as independent
predictors of NT-proBNP levels (p< 0.0001 for all). Patients
with higher CHADS2 and CHA2DS2VASc scores had
higher NT-proBNP levels. Among patients in the highest
quartile of NT-proBNP level >1,250 ng/l, 81.5% had
a CHA2DS2VASc score >2 in contrast to only 59% in the
lowest quartile of patients with NT-proBNP level363 ng/l.
NT-proBNP in relation to outcomes and study
treatment. In this substudy cohort, a total of 397 patients
(1.40%/year) experienced stroke or systemic embolism, and
1,075 (3.69%/year) died; 547 (1.88%/year) died of a cardiac
cause and 674 (2.61%/year) experienced a major bleeding
episode during a median follow-up of 1.9 years. Higher
baseline NT-proBNP concentration was strongly associated
Table 1 Demographics and Baseline Characteristics by Quartiles of NT-proBNP Level at Baseline
NT-proBNP Level
p Value363 ng/l 364-713 ng/l 714-1,250 ng/l >1,250 ng/l
n 3,725 3,721 3,724 3,722
Age, yrs 66.0 (59.0, 73.0) 69.0 (62.0, 75.0) 71.0 (65.0, 77.0) 73.0 (66.0, 79.0) <0.0001
Male 2,522 (67.7) 2,519 (67.7) 2,339 (62.8) 2,210 (59.4) <0.0001
Weight, kg 85.0 (73.4, 99.0) 85.0 (72.0, 99.0) 82.0 (70.0, 95.0) 76.4 (65.0, 89.1) <0.0001
Permanent or persistent atrial ﬁbrillation 2,215 (59.5) 3,384 (91.0) 3,516 (94.4) 3,522 (94.7) <0.0001
Calculated CrCl, ml/min 85.0 (66.9, 109.7) 79.3 (62.0, 101.0) 72.3 (56.8, 90.5) 60.2 (45.6, 78.0) <0.0001
CHADS2 risk factors
CHF or LVEF 40% 964 (25.9) 1,158 (31.1) 1,370 (36.8) 1,848 (49.7) <0.0001
Hypertension 3,320 (89.1) 3,273 (88.0) 3,277 (88.0) 3,165 (85.0) <0.0001
Age 75 yrs 718 (19.3) 1,006 (27.0) 1,293 (34.7) 1,549 (41.6) <0.0001
Diabetes mellitus 829 (22.3) 986 (26.5) 1,173 (31.5) 1,620 (43.5) <0.0001
Previous stroke or TIA 641 (17.2) 692 (18.6) 687 (18.4) 775 (20.8) 0.0009
CHA2DS2VASc risk factors
MI 368 (9.9) 396 (10.6) 497 (13.3) 652 (17.5) <0.0001
Previous PCI/CABG 394 (10.6) 478 (12.8) 549 (14.7) 599 (16.1) <0.0001
PAD 128 (3.4) 159 (4.3) 204 (5.5) 234 (6.3) <0.0001
Age 65–74 yrs 1,402 (37.6) 1,509 (40.6) 1,549 (41.6) 1,378 (37.0) <0.0001
Female 1,203 (32.3) 1,202 (32.3) 1,385 (37.2) 1,512 (40.6) <0.0001
CHADS2 score
1 1,600 (43.0) 1,348 (36.2) 1,174 (31.5) 935 (25.1) <0.0001
2 1,257 (33.7) 1,321 (35.5) 1,386 (37.2) 1,403 (37.7)
3 868 (23.3) 1,052 (28.3) 1,164 (31.3) 1,384 (37.2)
CHA2DS2VASc–score
1 524 (14.1) 370 (9.9) 227 (6.1) 178 (4.8) <0.0001
2 1,002 (26.9) 895 (24.1) 689 (18.5) 513 (13.8)
3 973 (26.1) 944 (25.4) 1,022 (27.4) 929 (25.0)
4 685 (18.4) 765 (20.6) 889 (23.9) 961 (25.8)
5 541 (14.5) 747 (20.1) 897 (24.1) 1,141 (30.7)
Medications
Aspirin 1,179 (31.7) 1,108 (29.8) 1,112 (29.9) 1,205 (32.4) 0.0313
Warfarin 1,851 (49.8) 2,102 (56.6) 2,146 (57.8) 1,901 (51.2) <0.0001
ACE inhibitor or ARB 2,575 (69.1) 2,600 (69.9) 2,650 (71.2) 2,710 (72.8) 0.0028
Calcium-channel blocker 1,242 (33.3) 1,269 (34.1) 1,139 (30.6) 902 (24.2) <0.0001
Beta-blocker 1,962 (52.7) 2,253 (60.5) 2,517 (67.6) 2,684 (72.1) <0.0001
Digoxin 795 (21.3) 1,191 (32.0) 1,317 (35.4) 1,523 (40.9) <0.0001
Values are n, median (Q1, Q3), or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; CABG ¼ coronary artery bypass graft; CHF ¼ congestive heart failure; CrCl ¼ creatinine clearance; LVEF ¼ left ventricular
ejection fraction; MI ¼ myocardial infarction; NT-proBNP ¼N-terminal pro–B-type natriuretic peptide PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; Q ¼ quartile; TIA ¼ transient
ischemic attack.
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2277with each of the major clinical outcomes examined except
major bleeding, even after adjustment for the multivariable
model (Fig. 1). For example, the annualized rate of stroke
or systemic embolism ranged from 0.74% in the bottom
NT-proBNP quartile (Q1: 363 ng/l) to 2.21% in the top
quartile (Q4: >1,250 ng/l); adjusted HR (Q4 vs. Q1): 2.35;
95% CI: 1.62 to 3.40; p < 0.0001) (Fig. 1). The adjusted
HR (Q4 vs. Q1) for all-cause mortality was 2.25 (95% CI:
1.80 to 2.81, p < 0.0001), and for cardiac mortality, it
was 2.50 (95% CI: 1.81 to 3.45, p < 0.0001). Higher
NT-proBNP was not associated with an increased risk of
major bleeding (adjusted HR [Q4 vs. Q1]: 1.07; 95% CI:
0.82 to 1.40; p ¼ 0.0667).
There was no signiﬁcant interaction between baseline
NT-proBNP levels and the effect of randomized treatmentin relation to any of these or the other study outcomes
(Fig. 2). Kaplan-Meier plots illustrating the associations
between NT-proBNP (by quartile) and these outcomes are
shown in Figure 3.
NT-proBNP levels in relation to CHA2DS2VASc score for
risk assessment and prognostic discrimination. Annual
rates of stroke or systemic embolism according to NT-
proBNP levels and CHA2DS2VASc score are illustrated in
Figure 4A. The rate increased with both increasing
CHA2DS2VASc score and higher NT-proBNP level. The
highest annual rate of stroke and systemic embolism (2.45%)
was found in the group with a CHA2DS2VASc score 3 and
an NT-proBNP concentration >1,250 ng/l, compared with
an average annual rate of 0.56% in patients with a CHA2DS2-
VASc score 2 and NT-proBNP levels 363 ng/l. Adding
Figure 1 Impact of Quartiles of NT-proBNP at Baseline on Outcomes
Cox proportional hazards model adjusted for established risk factors (age, sex, body mass index, smoking status, systolic blood pressure, heart rate, atrial ﬁbrillation type,
diabetes, heart failure, previous stroke/composite of stroke and systemic embolism/transient ischemic attack, hypertension, previous myocardial infarction, previous
peripheral artery disease/coronary artery bypass graft/percutaneous coronary intervention, treatment at randomization with aspirin, angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, and amiodarone for the major bleeding endpoint; history of anemia and of spontaneous or clinical relevant bleeding were also included),
randomized treatment, region, use of warfarin within 7 days before randomization, use of statin medication within 30 days before randomization score and biomarkers
(cystatin C and high-sensitivity troponin T). CI ¼ conﬁdence interval; HR ¼ hazard ratio; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; Pts ¼ patients; Q ¼ quartile.
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2278NT-proBNP to the CHA2DS2VASc score improved the
predictive model, with an increase in the C-statistic from
0.620 (95% CI: 0.592 to 0.647) to 0.646 (95% CI: 0.619 to
0.673) (p ¼ 0.0009) and a relative IDI improvement of 47%
(IDI: 0.0023; 95% CI: 0.0015 to 0.0030; p < 0.0001). For
cardiac deaths, increasing NT-proBNP levels had a distinc-
tively greater impact on outcomes than the CHA2DS2VASc
score groups (Fig. 4B). The C-statistic increased from 0.592
(95% CI: 0.568 to 0.617) to 0.691 (95% CI: 0.669 to 0.714)
(p < 0.0001), with a relative IDI improvement of 270%(IDI: 0.0142; 95% CI: 0.0119 to 0.0165; p < 0.0001)
compared with the CHA2DS2VASc alone. The ﬁndings
concerning the composite ischemic event endpoint (ischemic
stroke, systemic embolism, myocardial infarction, and cardiac
death) were very similar. The C-statistic increased from 0.598
(95% CI: 0.579 to 0.617) to 0.660 (95% CI: 0.641 to 0.678)
(p < 0.0001), with a relative IDI improvement of 162%
(IDI: 0.0119; 95% CI: 0.0099 to 0.0139; p < 0.0001). In
addition to IDI, a category-free (continuous) NRI analysis
was performed (Table 2). The continuous NRI was 0.289
Figure 2 Efﬁcacy of Apixaban Relative Warfarin for Quartiles of NT-proBNP Level at Baseline
Cox proportional hazards model with biomarker level, treatment, and interaction between treatment and biomarker level as covariates. Abbreviations as in Figure 1.
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2279(95% CI: 0.195 to 0.384, p < 0.0001) for stroke or systemic
embolism with events contributing 0.315 and nonevents
0.025. For vascular death, the continuous NRI was 0.508
(95% CI: 0.423 to 0.593, p < 0.0001) with events contrib-
uting 0.112 and nonevents 0.396. For stroke or systemic
embolism, the improved reclassiﬁcation was among patients
experiencing events, whereas for cardiovascular death, the
improvement was highest for nonevent patients.
Discussion
The major ﬁndings of this study were that NT-proBNP
levels are elevated in three-fourths of patients with AF and
at least 1 risk factor for stroke. The NT-proBNP concen-
tration was related to age, sex, and comorbidity, as expected,and most strongly to the type of AF, with higher levels
in patients with persistent/permanent AF compared with
paroxysmal AF. The NT-proBNP level was independently
and gradually related to the risk of stroke or systemic
embolism and all-cause and cardiac mortality. This pre-
dictive value of NT-proBNP was incremental to the
CHA2DS2VASc score and persisted after adjustment for
established risk factors including the CHA2DS2VASc score
and indicators of renal function and troponin. There was no
interaction between NT-proBNP and treatment (i.e., apix-
aban was superior to warfarin in terms of both efﬁcacy and
safety across NT-proBNP quartiles).
The prognostic value of natriuretic peptides is established
in elderly subjects living in the community and in patients
with stable coronary artery disease, acute coronary
Figure 3 Cumulative Hazard Rates for Study Endpoints by Quartiles of NT-proBNP
Cumulative hazard rates for stroke or systemic embolism (A); cardiac death (B); composite of stroke, systemic embolism (SEE), myocardial infarction (MI), and death (C); and
major bleeding (D). NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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Figure 4 Study Endpoint in Relation to NT-proBNP Levels and CHA2DS2VASc Score
Stroke and systemic embolism (A) and cardiac death (B) in relation to N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels and CHA2DS2VASc score.
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2281syndromes, and heart failure (10,12–15). Our study extends
these ﬁndings to subjects with AF and is consistent with the
recent ﬁndings of the RE-LY trial (11). However, because
there were considerably more patients in the present
ARISTOTLE biomarker cohort (N ¼ 14,892) compared
with RE-LY (N ¼ 6,189), we were able to demonstrate the
independent incremental value of adding NT-proBNP to a
recommended risk score (CHA2DS2VASc score) in rela-
tion to individual endpoints (e.g., subtypes of stroke
including intracranial bleeding). Despite adjustment for
established risk factors including CHA2DS2VASc score
and biomarkers reﬂecting different pathways of the renal
function (cystatin-C) and myocardial state (high-sensitivity
troponin T), the improved risk stratiﬁcation obtained with
NT-proBNP remained highly signiﬁcant, including more
than a doubled risk of stroke and cardiac death (Fig. 1).Further, a consistent risk over the duration of the trial was
seen in the NT-proBNP quartiles, allowing the identiﬁca-
tion of a greater absolute beneﬁt with apixaban compared
with warfarin treatment at higher NT-proBNP levels
(Fig. 2).
In clinical practice, risk stratiﬁcation in AF patients is
commonly based on clinical risk scores, such as the estab-
lished CHA2DS2VASc risk score, which is derived from
clinical variables such as the presence of congestive heart
failure, hypertension, age 75 years and older, diabetes,
previous stroke or transient ischemic attack, vascular
disease, age 65 to 74 years, and sex category. The present
study demonstrated the independent predictive value of
NT-proBNP in addition to clinical risk stratiﬁcation with
the CHA2DS2VASc score for improving the prognostic
discrimination of risk of stroke or systemic embolism and
Table 2 Category-Free Net Reclassiﬁcation Improvement
Outcome n Reclassiﬁcation Up Reclassiﬁcation Down NRI NRI Total (95% CI) p Value
Stroke/systemic embolism
Event subjects 397 261 136 0.315 0.289
(0.195–0.384)
<0.0001
Nonevent subjects 14,495 7,432 7,063 0.025
Cardiac death
Event subjects 543 302 241 0.112 0.508
(0.423–0.593)
<0.0001
Nonevent subjects 14,349 4,336 10,013 0.396
CI ¼ conﬁdence interval; NRI ¼ net reclassiﬁcation improvement.
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0.62 to 0.65 and 0.59 to 0.69 regarding stroke and cardiac
death events, respectively. For stroke or systemic embolism
events, the NT-proBNP levels and the CHA2DS2VASc
score distinctively provided complementary information,
as illustrated in Figure 4A. The lowest risk was seen in
patients with no or minimal elevated levels of NT-proBNP
(363 ng/l) and a low CHA2DS2VASc score (2).
Despite a CHA2DS2VASc score of 0 to 1, if the NT-
proBNP level was >1,250 ng/l, the annual risk of stroke
and systemic embolism equaled those with a score of 3
and levels 363 ng/l (Fig. 4A). Concerning cardiac death,
mainly NT-proBNP level, but not the CHA2DS2VASc score,
provided prognostic information, as visually illustrated in
Figure 4B, and with 270% improvement according to
relative IDI. For both outcomes, a substantial proportion of
patients were appropriately reclassiﬁed to higher or lower
risks as displayed with the category free NRI analysis.
The effect of study treatment in relation to NT-proBNP
levels was also analyzed in this study. NT-proBNP is an
established sensitive marker for heart failure (6). Heart
failure is a well-known risk factor for thromboembolism in
AF as well as an independent marker for increased bleeding
risk (4,22). We therefore analyzed the effect of the study
treatment in relation to NT-proBNP levels and cardiovas-
cular events including major bleeding. Despite the signiﬁ-
cant increased risk and predictive effect concerning stroke
or systemic embolism and mortality with increasing
NT-proBNP levels, there was no study treatment interac-
tion with regard to outcomes, thus displaying the superior
effect of apixaban over warfarin in terms of both efﬁcacy and
safety across NT-proBNP quartiles.
The clinical characteristics included in the CHA2DS2VASc
risk score have been identiﬁed primarily to provide in-
formation on stroke but not on other adverse events in AF
patients. Accordingly, also in relation to the composite
ischemic event endpoint, increasing NT-proBNP levels
were more strongly associated with outcomes than the
CHA2DS2VASc score, and the C-statistic increased from
0.60 to 0.66 (p < 0.0001). AF is a well-described risk factor
of increased mortality (1). Despite this evidence, in the
clinical setting, risk stratiﬁcation and treatment are mainly
focused on primary or secondary stroke prevention.
Although in an anticoagulated AF population such as in the
RE-LY and ARISTOTLE trial, the total numbers andannual rates of mortality are more than doubled compared
with stroke or systemic embolism events (23,24). This
study clearly displays the powerful risk prediction gained
with NT-proBNP measurements in an AF population
concerning mortality, both independently and compared
with CHA2DS2VASc score. This novel prognostic infor-
mation may be usable for treatment selection to further
improve survival in AF patients. The consistent results from
2 very large, systematic and prospective AF trials such as
RE-LY (11) and ARISTOTLE, together including 21,081
patients, enable deﬁnite conclusions of the incremental
prognostic value of NT-proBNP level for stroke, cardiac,
total death, and other ischemic events in patients with AF.
Several of the clinical variables used to assess ischemic
stroke risk in AF patients are also used to stratify the risk of
major bleeding events, of which the most devastating and
feared are the intracerebral hemorrhages (25). Due to the
large cohort size in the present study, we are, for the ﬁrst
time, able to discriminate and analyze subtypes of ischemic
or hemorrhagic stroke with regard to NT-proBNP levels.
The results clearly display a signiﬁcant elevated risk of
ischemic stroke with increasing NT-proBNP level (Fig. 1).
These novel ﬁndings add important information for the use
of NT-proBNP measurements for risk stratiﬁcation in stable
AF patients with regard to competing risks and thrombo-
embolic events.
In the present study, more than three-fourths of the
patients had NT-proBNP levels above the upper reference
limit for elderly individuals (17). AF rhythm rather than
sinus rhythm at the time of blood sampling was most
strongly associated with higher NT-proBNP levels, with
a >3-fold higher geometric mean. Persistent or permanent
compared with paroxysmal AF, older age, lower creatinine
clearance, and clinical history of coronary artery disease and
heart failure were also associated with higher NT-proBNP
levels in this AF cohort, which afﬁrms the results of some
previously published small studies (26). Elevated natriuretic
peptides reﬂect the myocyte response to increased wall
tension. In AF, levels of natriuretic peptides are elevated
compared with matched controls in sinus rhythm in various
settings (26–28) and decrease rapidly after restoration of
sinus rhythm (29–32). In contrast to the pathophysiology of
heart failure in which NT-proBNP is derived mainly from
the ventricles, there is support for NT-proBNP release from
the atrium in patients with AF as a response to atrial stretch
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may partly originate from atrial dysfunction, an established
marker associated with the formation of atrial thrombi (36),
and thereby provide a plausible mechanism for the prog-
nostic importance of elevated NT-proBNP levels and
thromboembolic events as presented in this ARISTOTLE
biomarker study.
Study limitations. The present ﬁndings are derived from
a clinical trial population with AF and at least 1 risk factor
for stroke and may therefore not be immediately extrapo-
lated to the general AF population. The study design does
not permit ﬁnal conclusions about the optimal cutoff value
of NT-proBNP as a decisive tool to select patients for
different antithrombotic strategies because all study partici-
pants received oral anticoagulants.
Conclusions
The NT-proBNP level is elevated in the majority of
patients with persistent or permanent AF. The degree of
NT-proBNP elevation has a strong independent association
with the risk of stroke and mortality. The relative beneﬁts of
apixaban compared with warfarin are consistent, regardless
of the NT-proBNP levels, and accordingly the absolute
beneﬁts of apixaban will be greater in patients with AF and
higher NT-proBNP levels. NT-proBNP might therefore be
a novel tool for the selection of patients with AF both for
anticoagulation and other treatments.
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